01—Abstract
Summary
Summary of the 8-K filed September 23, 2021. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. announced a significant addition to its Board of Directors with the appointment of Dr. Mikael Dolsten, effective September 21, 2021.
Dr. Dolsten brings a wealth of experience in the pharmaceutical and life sciences industries, most recently serving as Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer Inc. His appointment is expected to strengthen the board's expertise, particularly in areas related to research, development, and scientific innovation, which are critical to Agilent's strategic direction. Dr. Dolsten will serve on the Audit and Finance Committee and the Nominating/Corporate Governance Committee, indicating his intended active contribution to key board functions. The board size has been increased from 10 to 11 members to accommodate this appointment, and Dr. Dolsten has been deemed independent by the board, aligning with NYSE listing standards.
He has no disclosed conflicts of interest or pre-existing financial ties to Agilent stock, although Agilent does have ordinary course business relationships with Pfizer. Dr. Dolsten will receive standard non-employee director compensation, pro-rated for the current year.
02—Key points
Key Highlights
- Agilent Technologies appointed Dr. Mikael Dolsten to its Board of Directors, increasing board size to 11 members.
- Dr. Dolsten brings extensive experience from Pfizer, including roles as Chief Scientific Officer and President of Worldwide Research, Development and Medical.
- He will serve on the Audit and Finance Committee and the Nominating/Corporate Governance Committee.
- Dr. Dolsten is considered an independent director by the Board, meeting NYSE standards.
- There are no disclosed arrangements or understandings with others regarding his appointment, nor family relationships with current officers or directors.
- Dr. Dolsten currently holds no beneficial ownership of Agilent stock.
- Compensation will be in line with standard non-employee director pay, pro-rated for the current service period.
03—Questions
Frequently Asked Questions
Who is Dr. Mikael Dolsten and what is his background?
Dr. Mikael Dolsten is a seasoned executive with extensive experience in the pharmaceutical and life sciences sectors. He most recently served as Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer Inc. Prior to that, he held numerous senior leadership roles in research and development at Pfizer, Wyeth Pharmaceuticals, Orbimed Advisors, Boehringer Ingelheim, AstraZeneca, and Pharmacia & Upjohn.
Why has Agilent appointed Dr. Dolsten to its board?
The appointment of Dr. Dolsten, with his deep scientific and R&D expertise from major pharmaceutical companies like Pfizer, is intended to enhance the board's strategic oversight and guidance, particularly in areas crucial to Agilent's innovation-driven business model. His roles on key committees, including Audit and Finance and Nominating/Corporate Governance, suggest an active contribution to critical board functions.
Are there any potential conflicts of interest with Dr. Dolsten's appointment?
The company has stated that Dr. Dolsten meets independence standards set by the NYSE and has no arrangements or understandings related to his appointment. While Agilent does have ordinary course business relationships with Pfizer, Dr. Dolsten has no direct or indirect material interest in any transactions with Agilent and currently holds no beneficial ownership of Agilent stock, mitigating significant conflicts.
How will Dr. Dolsten be compensated?
Dr. Dolsten will receive the standard compensation paid to Agilent's non-employee directors. This compensation will be pro-rated to reflect the portion of the current year he will serve on the board. Details of the non-employee director compensation are available in Agilent's Proxy Statement filed on February 4, 2021.
04—Continue